Last reviewed · How we verify
NCT06253182: PEPP
Psychosexual Educational Partners Program (PEPP)
NA trial testing Self-Guided PEPP Intervention Workbook in Breast Cancer in 60 participants. Participants enrolled and being followed up; not accepting new ones.
30 September 2025
Quick facts
| Lead sponsor | The University of Tennessee, Knoxville |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 60 |
| Start date | 2 April 2024 |
| Primary completion | 30 September 2025 |
| Estimated completion | 30 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Self-Guided PEPP Intervention Workbook
- Self-Guided PEPP Education Workbook
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
- Sexual Dysfunction — all drugs for Sexual Dysfunction →
- Partner Communication — all drugs for Partner Communication →
Sponsor
The University of Tennessee, Knoxville
Who can join
Adults 18 to 99, any sex, with Breast Cancer or Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare two Psychosexual Educational programs for women who have completed treatment for breast or gynecological cancer and their partners in preparation for a well-powered phase III study. The investigators plan to enroll 30 dyads in a 2-arm pilot randomized controlled trial (RCT). The primary aim will be to assess the preliminary efficacy of the Psychosexual Educational Partners Program (PEPP) on sexual communication.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06253182
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other The University of Tennessee, Knoxville trials
Trials by the same sponsor.
- NCT07207993 — Evaluating Health Outcomes of AI-Based Fitness Wearables & App Programs in Elderly With Cognitive Decline · NA · not yet recruiting
- NCT06722261 — Single Case Research Design: Deaf Children's Language Outcomes · NA · active not recruiting
- NCT07023822 — WISH, Feasibility of a Factorial Design · NA · active not recruiting
- NCT06729164 — Strategic and Interactive Signing Instruction Experiment · NA · active not recruiting
- NCT06840028 — Effects of Personalized Exercise Prescriptions Through Mobile Health on Physical Activity and Health Outcomes in the Can · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06253182 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Tennessee, Knoxville
- Last refreshed: 24 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06253182.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing